- Home
- DCTH vs ERAS Comparison
DCTH vs ERAS Comparison
Compare DCTH & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCTH
- ERAS
- Stock Information
- Founded
- DCTH 1988
- ERAS 2018
- Country
- DCTH United States
- ERAS United States
- Employees
- DCTH N/A
- ERAS N/A
- Industry
- DCTH Medical/Dental Instruments
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- DCTH Health Care
- ERAS Health Care
- Exchange
- DCTH Nasdaq
- ERAS Nasdaq
- Market Cap
- DCTH 518.0M
- ERAS 432.6M
- IPO Year
- DCTH N/A
- ERAS 2021
- Fundamental
- Price
- DCTH $12.98
- ERAS $1.26
- Analyst Decision
- DCTH Strong Buy
- ERAS Strong Buy
- Analyst Count
- DCTH 4
- ERAS 6
- Target Price
- DCTH $22.75
- ERAS $4.83
- AVG Volume (30 Days)
- DCTH 494.6K
- ERAS 1.8M
- Earning Date
- DCTH 03-06-2025
- ERAS 05-07-2025
- Dividend Yield
- DCTH N/A
- ERAS N/A
- EPS Growth
- DCTH N/A
- ERAS N/A
- EPS
- DCTH N/A
- ERAS N/A
- Revenue
- DCTH $37,205,000.00
- ERAS N/A
- Revenue This Year
- DCTH $112.81
- ERAS N/A
- Revenue Next Year
- DCTH $61.78
- ERAS N/A
- P/E Ratio
- DCTH N/A
- ERAS N/A
- Revenue Growth
- DCTH 1701.69
- ERAS N/A
- 52 Week Low
- DCTH $4.26
- ERAS $1.04
- 52 Week High
- DCTH $16.97
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- DCTH 44.79
- ERAS 36.09
- Support Level
- DCTH $12.18
- ERAS $1.40
- Resistance Level
- DCTH $14.61
- ERAS $1.61
- Average True Range (ATR)
- DCTH 0.77
- ERAS 0.12
- MACD
- DCTH -0.00
- ERAS -0.01
- Stochastic Oscillator
- DCTH 33.47
- ERAS 38.60
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.